Amikacin, plasma or serum
amikacin and rapidly aggregate in the presence of an amikacin antibody solution. When a sample containing amikacin is introduced, the aggregation reaction is partially inhibited, slowing the rate of the aggregation process. Antibody bound to sample drug is no longer available to promote microparticle aggregation, and subsequent particle lattice formation is inhibited. Thus, a classic inhibition curve with respect to amikacin concentration is obtained, with the maximum rate of aggregation at the lowest amikacin concentration. By monitoring the change in scattered light or absorbance, a concentration‑dependent curve is obtained.
Serum, Plasma (Heparin)
120 uL
Amikacin is indicated in the short term treatment of serious gram negative infections (Pseudomonas, Escherichia coli). It is particularly useful with those strains resistant to most other aminoglycosides of choice when gentamicin resistance is suspected.
As with other aminoglycosides, there is a narrow margin between therapeutic effectiveness and toxicity. Amikacin should be used with caution in patients with impaired renal function.
Toxic side effects may include: ototoxicity (hearing loss), neuromuscular blockage (muscle paralysis) and nephrotoxicity.
Antibiotic
Browse tests by laboratory
Customer Service
Toll Free: 1-855-381-3212
Local: 416-813-7200

